Vaccinex has developed a proprietary platform called ActivMAb to enable the efficient identification of high-affinity, full-length human monoclonal antibodies with built-in manufacturability and favorable biophysical properties ideally suited for downstream development.  We took the throughput and flexibility of phage and yeast display and migrated it to mammalian cells.  We have used this platform for the discovery and development of human therapeutic monoclonal antibodies to treat serious diseases with unmet needs.  We can help you select antibodies against your therapeutic targets of interest.  Use this link to request more information about our ActivMab services.  Use the links on the left to learn more about our innovative approach.


See our write-up in Nature Biopharma Dealmakers!